Sai Parenterals subsidiary wins AUD 202M Australian OTC supply deal

Order Above 5pct RevenueExport Order Hard CurrencyBusiness Updates View source PDF

SAIPARENT · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.4%1-day move

₹617.95

prior close

₹676.15

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-4.2-4.5-6.0-5.3+0.4-1.3-3.2-4.4-3.9-5.0-13.1———

Up moveDown movePending

AI summary

Sai Parenterals' subsidiary Noumed Pharmaceuticals has signed an exclusive 7.5-year OTC medicine supply agreement with Australia's leading pharmacy network. The contract value is AUD 202 million, roughly equal to INR 1,300 crores. Deal starts July 1, 2026, with an option to extend by 3 more years on mutual consent. It is an international contract and not a related-party transaction.

Likely market impact

Major export win worth around INR 1,300 crores over 7.5 years strengthens long-term revenue visibility for retail shareholders.